Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Abstract

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.

• Authors: Melody Smith, Elena García-Martínez, Michael R Pitter, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
• Journal: Oncoimmunology (Oncoimmunology) 2018 Vol. 7 Issue 12 Pg. e1526250 ISSN: 2162-4011 [Print] United States
• PMID: 30524908 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)